Trial intelligence / Profile preview

Phase III velzatinib vs imatinib in untreated metastatic/unresectable GIST

CTR20262439Phase 3Active

Sponsor
不适用/ 葛兰素史克(中国)投资有限公司
Start
Aug 2026
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 3 trial of IDRX-42 in gastrointestinal stromal tumor (GIST), sponsored by 不适用/ 葛兰素史克(中国)投资有限公司. Started Aug 2026; status: active.

02

Drugs

IDRX-42
03

Conditions

gastrointestinal stromal tumor (GIST)

Beyond the preview

Go deeper on CTR20262439.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20262439.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call